Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients
|ClinicalTrials.gov Identifier: NCT00058734|
Recruitment Status : Completed
First Posted : April 14, 2003
Last Update Posted : August 27, 2007
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Biological: Dendritic Cells Pulsed with HIV antigens||Phase 1|
The novel strategy used in this trial is to mix a peptide vaccine with dendritic cells from individuals. The dendritic cells are normal cells in the blood that boost immune responses. In HIV uninfected people, dendritic cells have been found to strongly activate the types of immune responses that may be important in controlling HIV.
HIV infected and HIV uninfected individuals in this study will receive one shot of dendritic cells alone followed by three monthly shots of dendritic cells plus vaccine. We will monitor the immune responses to the peptide vaccine during this time period. After completing the vaccinations, HIV infected patients will stop their HIV medications and their immune status (CD4 count) and viral load will be monitored closely over 12 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Immune Responses to Antigen-Bearing Dendritic Cells in HIV-Infected Individuals|
|Study Start Date :||November 2000|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00058734
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Nina Bhardwaj, MD, PhD||New York University|